Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin Plus Toripalimab With Cetirizine and Mecobalamin in Advanced Bladder Cancer
NCT07853053Phase 1Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jan 2027
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of disitamab vedotin and toripalimab in bladder cancer, sponsored by Sun Yat-sen Memorial Hospital. Primary endpoints: Objective Response Rate and Incidence of Treatment-Related Grade 2 or Higher Peripheral Neuropathy. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
disitamab vedotintoripalimab
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT07853053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07853053.